Glaukos (GKOS) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Glaukos (GKOS) do?
Glaukos Corp (GKOS) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures microscopic surgical stents that drain intraocular fluid to treat glaucoma. Builds microscopic surgical stents and slow-release intraocular implants to reduce fluid pressure inside the eye. It is worth $14.09B on the market and sold $690.24M over the last year.
- Market cap
- $14.09B
- P/E ratio
- None (reported a loss)
- Annual sales
- $690.24M
- Sector
- Healthcare
- Industry
- Medical Devices
- Brief updated
- Nov 17, 2026
Brands and businesses behind GKOS
- iStent: Microscopic titanium implants sold to ophthalmic surgeons to reduce internal fluid pressure in patients with glaucoma.
- Photrexa: Prescription riboflavin eye drop formulations sold to treat progressive corneal thinning through photo-activation therapy.
- iDose TR: An implantable drug delivery device that continuously releases travoprost directly into the anterior chamber of the eye.
GKOS’s flags, in plain English
Each flag is a number from Glaukos’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 17, 2026.
Stupid Cash
Can pay this year's bills 4.6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Wide Gross Margin
Gross margin of 81.1% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Low debt
Low debt, only 14% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.
Burning Cash
Losing money, profit margin of -24.6%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
1 more green flag open with the free trial. Try it free for 7 days.
Questions about GKOS
How big is Glaukos?
Glaukos’ market cap is $14.09B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $690.24M: what customers paid the company over the last year, before any costs.
What is GKOS’s P/E ratio?
GKOS has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with GKOS?
The business relies heavily on Medicare fee schedules and reimbursement coding for eye stent procedures. That is one risk on Glaukos’ card. Its first risk flag is Burning Cash, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Glaukos’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. GKOS’s filings on SEC.gov. The Margin Monkey is research, not advice.
